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Abstract
Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence
or absence of a potential glycosylation site at amino acid residues 154–156 in the HA1 region of the viral hemagglutinin (HA) surface
glycoprotein. To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine
constructs that differed in the presence of potential glycosylation sites at amino acid residues 154–156, 165–167, and 286–288 were used
to immunize BALB/c mice. Postvaccination serum IgG, hemagglutination inhibition, and neutralizing antibody titers as well as the
morbidity and mortality following a lethal H5N1 viral challenge did not vary significantly among any of the experimental groups. We
conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA
vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those
of closely related H5 viruses.
© 2003 Elsevier Science (USA). All rights reserved.
Keywords: H5N1; Avian influenza; DNA vaccines; Hemagglutinin; Glycosylation
Introduction
The hemagglutinin (HA) is the major surface glycopro-
tein of the influenza virus that mediates the attachment and
penetration of the virus into host cells. The HA is produced
as a polyprotein that is proteolytically cleaved into two
subunits, HA1 and HA2, which are held together by a single
disulfide bond. The HA2 anchors the molecule into the lipid
membrane and is responsible for the oligomerization of the
protein into its trimeric form. HA1 forms the globular head
of the molecule, containing the receptor binding site and
conformationally dependent epitopes that are the primary
targets for neutralizing antibodies (Dowdle et al., 1974;
Kilbourne and Kehoe, 1975; Webster et al., 1975). The HA
is therefore the primary focus of current inactivated influ-
enza virus vaccines. However, continual variation in the HA
either through the gradual accumulation of point mutations
(antigenic drift) or through occasional acquisition of a novel
HA gene (antigenic shift) demands the annual reformulation
of influenza vaccines (Caton et al., 1982; Raymond et al.,
1986; Skehel et al., 1984; Wiley and Skehel, 1987; Wiley et
al., 1981; Wilson et al., 1983).
The HA undergoes posttranslational, host-cell-dependent
glycosylation. The main purpose of glycosylation on the
HA is to aid in correct folding of the molecule and in the
formation of the HA trimer. Although all HA molecules are
glycosylated, with one exception, the location and number
of potential glycosylation sites are not conserved among
HAs of different strains and subtypes (Keil et al., 1984;
Wilson et al., 1983). The number of sites varies between 5
and 11 in different influenza A strains with general conser-
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vation of the glycosylation sequence occurring around res-
idues 20–22 in HA1. The potential glycosylation sites are
scattered throughout the HA protein, but tend to cluster
around the antigenic sites in HA1 (Matrosovich et al., 1999;
Wilson and Cox, 1990). The presence or absence of a given
host-derived carbohydrate moiety can modulate the antige-
nicity of the HA molecule by preventing the binding of
neutralizing antibody or by masking epitopes recognized by
CD4 T cells (Skehel et al., 1984; Wiley and Skehel, 1987).
This has also been shown recently with the glycosylation of
the envelope glycoprotein of the human immunodeficiency
virus (Quinones-Kochs et al., 2002). Thus, the acquisition
of carbohydrate moieties provides a mechanism for evasion
from the immune system.
In 1997, avian influenza A (H5N1) viruses were identi-
fied as the causative agent of 18 cases of human respiratory
illness, including six deaths in Hong Kong (Center, 1997,
1998; Subbarao et al., 1998). Human H5N1 isolates were
divided into two distinct groups based on antigenic differ-
ences when tested against reference postinfection ferret an-
tisera by the hemagglutination-inhibition (HI) assay
(Bender et al., 1999). In addition, the two groups differed
genetically due to the absence (Group A) or presence
(Group B) of a potential glycosylation site (N-X-S/T, X 
P) at amino acids (aa) 154–156 in HA1, located at the tip of
the globular head domain of HA.
The ability of avian H5N1 viruses to infect and cause
severe respiratory illness in humans highlighted the pan-
demic potential of this virus and the need for an effective
vaccine. Traditional strategies have, as yet, failed to produce
a suitably immunogenic vaccine against the H5N1 viruses
(Lu et al., 1999; Nicholson et al., 2001; Treanor et al., 2001;
Wood et al., 1999). Immunizing with purified DNA is a
powerful technique for inducing immune responses. Com-
parative studies of conventional and influenza HA-based
DNA vaccines have shown that DNA vaccination is equiv-
alent to immunization with a live virus vaccine in protecting
mice from challenge and both vaccines were superior to a
subunit vaccine (Boyle et al., 1996; Justewicz et al., 1995).
While carbohydrate moieties clearly can modulate the an-
tigenicity of HA, little is known about the impact of glyco-
sylation on the quantity or quality of the antibody response
to a DNA-expressed HA vaccine. To investigate the impact
of glycosylation on the immunogenicity of an H5 HA-
expressing DNA vaccine, BALB/c mice were vaccinated
with plasmids that were engineered to differ in the presence
or absence of potential glycosylation sites in the globular
head domain of HA1. Based on the analysis of H5 HA
sequences from 1959 to 1997, three potential glycosylation
sites (residues 156, 167, and 288) that were not conserved in
all H5 strains were chosen since these sites were likely not
critical for the structural integrity of the folded protein.
However, these sites were conserved in 14 of 15 highly
pathogenic H5 viruses in our analysis, suggesting a role for
these carbohydrate moieties in viral pathogenesis (Matroso-
vich et al., 1999). While the crystal structure of the H5 HA
has recently been determined (Ha et al., 2001), the antigenic
sites on the H5 HA are not yet fully defined. Recent studies
have identified two antigenic sites on the H5 HA, using
monoclonal antibody escape mutants. Based on this work,
the glycosylation site at residue 156 is in or near the anti-
body-combining site B (Kaverin et al., 2002). By analogy
with the H3 HA structure, the glycosylation site at residue
167 would also be in or near antigenic site B, whereas the
glycosylation site at residue 288 would be in or near anti-
genic site C (Wilson and Cox, 1990). Here we show that an
HA-expressing DNA vaccine protected animals from chal-
lenge with a highly lethal H5N1 virus and that altering the
glycosylation pattern on H5 HA did not substantially alter
the quantity or quality of the neutralizing antibody response
in BALB/c mice.
Results
Generation and expression of plasmids
In preliminary experiments, the entire HA coding se-
quence from the influenza HK/156 and HK/483 viruses was
cloned into the pGA expression vector to raise polyclonal
rabbit antisera by gene gun immunization of New Zealand
white rabbits with the plasmids. Rabbits inoculated three
times with 12 g of DNA expressing the HA from HK/156
lacking a potential glycosylation site at aa 154–156 in the
globular head domain of HA1 elicited higher titers of
anti-HA antibodies than the titers from rabbits inoculated
with a DNA vaccine expressing the HK/483 HA, which
contains a potential glycosylation site at these residues.
These results suggested that the extent of glycosylation may
impact the immunogenicity of the HA molecule expressed
in a DNA vaccine construct.
To investigate the impact of the glycosylation state of the
HA on the immunogenicity of this protein, DNA plasmids
expressing either the wild-type HK156 or the mutated HA
were constructed. The HK156wt DNA plasmid contained
N-linked potential glycosylation sites at amino acids 165
and 288, while five additional HA expression plasmids were
constructed that expressed the HK/156 HA gene mutated to
contain various combinations of N-linked potential glyco-
sylation sites at amino acids 156, 167, or 288 by site-
directed mutagenesis (Fig. 1). Each HA gene was cloned
into the pGAT0 mammalian expression vector (Fig. 1).
To verify expression of each HA protein, DNA vaccine
plasmids were transiently transfected into human 293T cells
and the cell lysates were assayed for expressed HA. Each
gene product was expressed and detected as a band of 65–70
kDa using polyclonal rabbit antisera raised against the
HK156wt HA. We observed an upward or downward shift
of the HA bands on the Western blot, indicating an alter-
ation in the size of the expressed protein consistent with the
addition (RB536) or deletion (RB537, RB539, RB552,
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RB553) of glycosylation sites, respectively (data not
shown).
Antibody responses of mice immunized with HA
expressing DNA vaccines
The ability of the HA-expressing DNA vaccines to in-
duce serum ELISA, HI, and neutralizing antibodies to the
homologous HK/156 virus was examined. Groups of mice
(n  10) were vaccinated with 1 g of HK156wt, RB536,
RB537, RB539, RB552, or RB553 HA-expressing plasmid
or 1 g of pGAT0 vector with no insert for a negative-
control DNA. Four weeks later, the mice were boosted with
1 g of plasmid DNA. Sera collected 4, 6, 10, and 14 weeks
after the first immunization were analyzed for the presence
of H5-specific antibodies by ELISA, HI, and neutralization
assays.
IgG antibody titers in sera collected 4 weeks after the
first inoculation and 2 weeks after the boost were measured
using an ELISA with a purified, recombinant HK/156 HA
protein to coat the plates. Each of the constructs elicited a
substantial H5 HA-specific IgG response after the first in-
oculation, suggesting that each construct was adequately
delivered and expressed in mice. A 10- to 15-fold boost in
IgG antibody response was seen with each construct after
the second inoculation. There was no significant difference
in serum IgG antibody levels raised toward any expressed
HA when compared with the HK156wt HA (Fig. 2).
To assess the quantity of functional antibodies elicited by
the various HA-expressing constructs, the HI assay, the
“gold standard” for serological measurement of an immune
response to influenza, was used to detect antibody against
homologous HK/156 virus. Because the HI assay was
shown previously to be less sensitive for the detection of
antibodies induced by avian influenza viruses, we also used
the more sensitive microneutralization assay (Rowe et al.,
1999). At week 14, the titer of HI antibodies was signifi-
cantly higher in the group inoculated with RB553, when
compared to the HK156wt (P  0.05) (Fig. 2). The micro-
neutralization assay showed that, in general, there was no
significant difference in neutralizing antibody titers at week
6. However, at week 14 the neutralizing antibody titer raised
by the RB537-expressed HA was significantly lower than
that induced by the HK156wt (P  0.05) (Fig. 2). Overall,
these results indicate that there was little difference in the
ability of each mutated HA to raise functional antibodies
when compared to the wild-type HA against a homologous
virus.
Specificity of neutralizing antibodies raised against the
DNA-expressed HA
Since there was no difference in the relative quantity of
neutralizing antibodies raised, we next determined whether
differences in glycosylation in HA1 affected the extent of
cross-reactivity of the antibody response. Sera collected at
week 14 from each vaccine group were pooled and tested
for the ability to neutralize closely or more distantly related
H5 influenza viruses as well as viruses of other subtypes
(H1, H3, and H9) (Table 1). None of the sera from any
vaccine group was able to neutralize viruses from the H1,
H3, or H9 subtypes or the H5 viruses Ty/Wis or Ck/Scot,
which shared 90% similarity in their amino acid sequence
compared to the HK/156 HA (data not shown). The neu-
tralizing antibody titers for the other H5 viruses are shown
in Fig. 3. Neutralizing antibody titers against the closely
related HK/483 virus were similar to those against the
wild-type HK/156 virus. There was a direct correlation
between the percentage amino acid homology of the HA
and the ability to neutralize virus. As the percentage of
Fig. 1. Schematic representation of vector DNA constructs used for im-
munizations. (A) The pGAT0 vector contains the cytomegalovirus imme-
diate-early promoter (CMV-IE) plus Intron A (IA) for initiating transcrip-
tion of eukaryotic inserts and bovine growth hormone polyadenylation
signal (BGH poly(A)) for termination of transcription. The vector also
contains the CoIE1 origin of replication for prokaryotic replication as well
as the Kanamycin resistance gene (Kanr) for selection in antibiotic media.
The lambda T0 terminator has been placed 3 to the Kanr to increase the
stability of eukaryotic inserts. HA inserts were cloned into the vector using
the HindIII and BamHI restriction endonuclease sites. (B) Schematic of a
truncated H5 HA1 region illustrating the pattern of three potential glyco-
sylation sites altered in the listed vaccine constructs.
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amino acid homology decreased, the neutralizing antibodies
induced by the constructs lost the ability to neutralize these
viruses, regardless of the glycosylation pattern of the HA
used as an immunogen. Therefore, neutralizing antibodies
induced by the HK/156 DNA vaccines showed minimal
differences in their ability to recognize the HA from closely
related H5 viruses and did not show any heterosubtypic
reactivity.
Fig. 2. Antibody responses to HK156 HA-expressing DNA vaccines with different glycosylation patterns. Groups of 10 mice were inoculated on day 0 and
at week 4 with 1 g plasmid DNA via gene gun to the abdominal epidermis. (A) ELISA serum IgG antibody titer to HK/156 rHA. Sera were collected at
weeks 4 and 6 to determine IgG antibody levels after one and two inoculations, respectively. IgG titers are expressed as log10 endpoint titers. (B)
Hemagglutination-inhibition (HI) antibody titers measured against HK/156 virus in sera collected at weeks 4, 6, and 14. HI titers are expressed as the log2
value of the reciprocal of the highest dilution of serum inhibiting agglutination of 0.5% turkey erythrocytes by 4 HA units of virus. (C) Neutralizing antibody
titers measured against HK/156 virus in sera collected at weeks 4, 6, and 14. Neutralizing titers are expressed as the log2 value of the reciprocal of the highest
dilution of serum neutralizing antibodies inhibiting 100 TCID50 of virus growth in MDCK cells. *P  0.05 for experimental group versus HK156 wild-type
HA. (Open bars, week 4; shaded bars, week 6; filled bars, week 14.)
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Protection against influenza in mice immunized with wild-
type or nonglycosylated HA-expressing DNA vaccines
To determine the extent of protection provided by each
of the HA-expressing plasmids, mice were challenged with
the HK/156 virus. Fourteen weeks after the first inoculation,
groups of six mice were challenged intranasally with 10
MLD50 of HK/156. In addition to the DNA-inoculated
mice, a naı¨ve group of mice was infected as a control.
Weight loss and survival was monitored daily for 14 days.
Fig. 4 presents the data for the individual groups of mice.
Substantial weight loss and death were seen in the naı¨ve
mouse group and in mice that received the empty vector
DNA. The RB537 group was the only group to show a
substantial, yet transient weight loss. Both RB536- and
RB537-inoculated groups had one mouse succumb to infec-
tion on days 7 and 8, respectively. Therefore, all HA-
expressing plasmids induced 83 to 100% protection of mice
from lethal challenge with H5N1 virus. These results indi-
cate that there was no significant difference in the ability of
each DNA construct to protect mice against a lethal homol-
ogous challenge.
Discussion
In this study, we have investigated the relative immuno-
genicity and protective efficacy of DNA vaccines express-
ing HK/156 HA and containing different glycosylation pat-
terns at three sites within HA1 in mice. The different
patterns of glycosylation in the HA1 did not significantly
alter the quantity of neutralizing antibodies raised in the
mice nor did they affect the cross-reactivity of antibodies
for related H5 viruses. Protection of mice against lethal
challenge with H5N1 virus was achieved from each DNA-
expressing HA vaccine with varying patterns of the glyco-
sylation in the HA1 region. Only one group, RB537,
showed a modest reduction in the neutralizing antibody
titer, resulting in the death of one mouse, which may reflect
a single poor-responder to vaccination. This study confirms
Table 1
Genetic relatedness of influenza viruses based on amino acid sequence
homology of the hemagglutinin (HA)
Virus Subtype % homology—
HK156 HA
A/Puerto Rico/8/34 H1N1 63.6
A/Sydney/5/97 H3N2 37.8
A/Hong Kong/1073/99 H9N2 49.2
A/Hong Kong/156/97 H5N1 100
A/Hong Kong/483/97 H5N1 98.6
A/Duck/Singapore-Q/F119-3/97 H5N1 94.0
A/Duck/Hong Kong/79 H5N3 93.3
A/Chicken/Scotland/1/59 H5N1 90.6
A/Mallard/Wisconsin/944/92 H5N2 89.9
A/Turkey/Wisconsin/1/68 H5N3 89.4
Fig. 3. Neutralizing antibody titers to H5 influenza viruses. Week 14 sera from 10 mice per group were pooled and tested for the ability to neutralize 100
TCID50 of closely related H5 influenza viruses. The data are expressed as the log2 value of the reciprocal of the highest dilution of sera able to neutralize
the respective virus.
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and extends previous results from preclinical studies dem-
onstrating that an H5 HA-expressing DNA vaccine can
provide protection from fatal H5N1 disease that was asso-
ciated with systemic spread and an inflammatory response
in the brain of BALB/c mice (Kodihalli et al., 1999).
The avian outbreak of H5N1 viruses in 1997 that caused
respiratory disease and death in humans and the subsequent
occurrence of an H9N2 infection in humans highlighted the
potential threat of such novel avian subtypes for further
infections among susceptible humans. Since that time,
H5N1 viruses have reemerged in live poultry markets in
Hong Kong several times, while H9N2 viruses remain wide-
spread in domestic poultry throughout Asia (Cauthen et al.,
2000; Guan et al., 2000; Webster et al., 2002). The potential
for novel avian subtypes to reassort with human viruses and
create a pandemic strain necessitates the evaluation of cur-
rent and alternative vaccine approaches to provide protec-
tion in such an event. Several approaches have been used in
mice to generate an H5N1 vaccine; using traditional inac-
tivated vaccines based on the highly pathogenic H5N1 virus
itself, an antigenically related apathogenic H5N3 virus, or a
baculovirus-produced recombinant H5 HA protein. Al-
though the inactivated H5N1 vaccine was immunogenic and
protected mice from a lethal H5N1 challenge (Wood et al.,
1999), the lethality of the virus for chicken embryos, result-
ing in suboptimal virus titers (Takada et al., 1999), and the
need for BSL3 containment for vaccine production, limits
the utility of this approach (Wood et al., 1999). The use of
Fig. 4. Weight loss and survival in mice administered HA-expressing DNA vaccines. Groups of six mice were inoculated with 1 g of plasmid DNA on day
0 and at week 4. Fourteen weeks after the initial inoculation, mice were challenged with 10 LD50 of HK/156 virus and monitored for 14 days. (A) Mean weight
loss expressed as a percentage of original weight. (B) Percent survival (}, pGA vector; , HK156wt (  ); , RB536 (  ); E, RB537 (  );
F, RB539 (  ); ‚, RB552 (  ); Œ, RB553 (  ); {, unvaccinated).
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the surrogate, apathogenic virus, Dk/Sing, as a traditional
vaccine overcame the need for containment facilities. How-
ever, in both mice and humans the immunogenicity of two
doses of inactivated Dk/Sing was suboptimal and required
the use of adjuvants for improved immunogenicity (Lu et
al., 1999; Nicholson et al., 2001; Wood et al., 1999). Like-
wise, the baculovirus recombinant H5 HA vaccine induced
suboptimal immunity in humans (Treanor et al., 2001). In
light of these results, it is important to examine the efficacy
of alternative vaccine strategies such as DNA vaccines for
H5 viruses. Studies on preclinical efficacy showed that
DNA expression vectors encoding the influenza HA, plus
NP and M1, in ferrets and nonhuman primates were as
effective as conventional inactivated vaccines in reducing viral
shedding (Donnelly et al., 1995). DNA vaccines expressing the
HA of HK/156 also protected mice from a lethal challenge of
homologous virus, even in the absence of detectable HI anti-
body titers (Kodihalli et al., 1999). In addition, it has been
shown that DNA vaccines based on conserved influenza pro-
teins, NP and M1, from the PR8 virus could provide hetero-
subtypic protection and control the infection of mice with
the mildly pathogenic HK/156 virus (Epstein et al., 2002).
DNA vaccines offer two main advantages for the devel-
opment of a pandemic influenza vaccine. First, a DNA
vaccine can be rapidly prepared simply by cloning the
relevant HA, with or without other viral genes, into an
appropriate plasmid-based expression vector as soon as a
novel virus with pandemic potential is identified. In cases
where a highly pathogenic avian virus is detected, DNA
vaccines overcome the limitations of growth in embryo-
nated eggs and the need for containment facilities. How-
ever, to date, DNA vaccines expressing influenza HA have
failed to elicit substantial antibody responses in humans,
although only intramuscular delivery has been evaluated.
Particle-mediated or gene gun delivery modalities may well
improve DNA vaccine immunogenicity in humans as has
been shown in animal models including nonhuman primates
(Kent et al., 2001; Lodmell et al., 2001).
This study has demonstrated that differences in number
of nonconserved glycosylation sites within HA1 of a given
subtype of influenza should not affect the ability to elicit
neutralizing antibodies of DNA-expressed proteins. Fur-
thermore, differences in HA1 glycosylation patterns also
had no effect on the degree of antibody cross-reactivity
between related strains. We conclude that DNA vaccines
should be evaluated further as a preventative strategy
against pandemic influenza.
Materials and methods
Viruses
The influenza viruses used in this study were A/Hong
Kong/156/97 (HK/156), A/Hong Kong/483/97 (HK/483),
and A/Chicken/Scotland/1/59 (Ck/Scot) (all H5N1);
A/Duck/Hong Kong/79 (Dk/HK), A/Duck/Singapore-Q/
F119-3/97 (Dk/Sing), and A/Turkey/Wisconsin/1/68 (Ty/
Wis) (all H5N3); A/Mallard/Wisconsin/944/82 (Mal/Wis)
(H5N2); A/Puerto Rico/8/34 (PR/8) (H1N1); A/Aichi/2/68
(Aichi) (H3N2); and A/Hong Kong/1073/99 (H9N2). A
U.S. Department of Agriculture permit was obtained before
work with avian influenza viruses was begun. Virus stocks
were propagated in the allantoic cavities of 10-day-old em-
bryonated hen eggs under conditions that were found to be
optimal for virus replication (Lu et al., 1999). Virus stocks
were stored at 70°C until use.
Due to the potential risk to humans and poultry, all
experiments using infectious pathogenic avian viruses, in-
cluding animal challenges, were conducted using BSL3
containment procedures (Richmond and McKinney, 1993).
Investigators were required to wear appropriate respirator
equipment (RACAL Health and Safety, Inc., Frederick, MD).
Plasmids and mutagenesis
A full-length cDNA copy of the HA gene of HK/156 was
cloned into a pUC19 vector. The full-length HA gene from
this clone was obtained by digestion with HindIII-BamHI
restriction enzymes, and the resulting fragments were li-
gated into a pGAT0 mammalian expression vector that has
been previously described (Ross et al., 2000). This plasmid
construct was designated HK156wt. Primers used for mu-
tagenesis of the HK156wt HA gene to create the plasmids
RB536, RB537, RB539, RB552, and RB553 were S288A:
F-gcgataaactctgctatgccattccac, R-gtggaatggcatagcagaggtt-
tatcgc; A156T: F-caaaaagaacagtacatacccaacaataaa, R-ctttat-
tgttgggtatgtactgttctttttg; and T167A F-ggagctacaataatgc-
caaccaagaag, R-cttcttggttgttggcattattgtagctcc. Mutations
were made using a 16-cycle PCR reaction with the Quick-
Change Mutagenesis Kit (Life Sciences, Carlsbad, CA) fol-
lowing the manufacturer’s guidelines. The expression plas-
mids along with their specific glycosylation pattern at the
three targeted sites are listed in Fig. 1.
The plasmids were amplified in the DH5 Escherichia coli
strain, purified using anion-exchange resin columns (Qiagen,
Valencia, CA), and stored at 20°C in dH2O. Plasmids were
verified to contain the correct size gene insert of 1.7 kb by
digestion with HindIII-BamHI restriction enzymes and gel
electrophoresis. The constructs were also fully sequenced
through the HA-insert region to confirm that only the muta-
tions of interest were made. Purity of DNA preparations was
determined by optical density readings at 260 and 280 nm.
Transfections and expression analysis
The human embryonic kidney cell line, 293T (5  105
cells/transfection), was transfected with 2 g of DNA using
12% Lipofectamine according to manufacturer’s (Life
Technologies, Grand Island, NY) guidelines in 1 ml of
DMEM without fetal calf serum (FCS) in one well of a
six-well plate. After overnight incubation, the transfection
mixture was aspirated and replaced with 2 ml of fresh
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DMEM containing 10% FCS plus antibiotics. Cells were
incubated for an additional 48 h at 37°C in 5% CO2. Cell
lysates were collected in 300 l of RIPA lysis buffer
(0.05M Tris–HCI, pH 8.0, 0.1% Triton X-100, 2 mM phe-
nylmethylsulfonyl fluoride (PMSF), 0.15 M NaCI) and
stored at 70°C.
For Western blot analysis, 30 g of total protein from
each cell lysate was diluted 1:2 in SDS sample buffer
(Bio-Rad, Hercules, CA) and loaded onto a 10% SDS–
polyacrylamide gel. The resolved proteins were transferred
onto a nitrocellulose membrane (Bio-Rad) and incubated
with a 1:2000 dilution of polyclonal rabbit anti-H5 HA
antisera in PBS containing 0.1% Tween 20 and 1% nonfat dry
milk. After extensive washing of the membrane, bound rabbit
antibodies were detected using a 1:2000 dilution of horse-
radish peroxidase conjugated goat anti-rabbit antiserum and
enhanced chemiluminescence (Amersham, Piscataway, NJ).
Mice and DNA immunizations
Female BALB/c mice, 6 to 8 weeks old (Charles River
Laboratories, Wilmington, MA), were used in all experi-
ments. Mice, housed in microisolator units and allowed free
access to food and water, were cared for under USDA
guidelines for laboratory animals under an approved insti-
tutional protocol. Mice were anesthetized with 0.03–0.04
ml of a 5:1 mixture of ketamine HCI (100 mg/ml) and
xylazine (20 mg/ml). Gene gun immunizations were per-
formed on shaved abdominal skin using the previously
described hand-held Accell gene delivery system (Haynes et
al., 1994; Pertmer et al., 1995; Pertmer and Robinson,
1999). Mice were immunized at week 0 and boosted at week
4 with 1 g of DNA containing 0.5 g of DNA per 0.5 mg
of 1-m gold beads (DeGussa-Huls Corp., Ridgefield
Park, NJ) at a helium pressure setting of 400 psi.
Serologic testing
Postvaccination sera from blood samples (weeks 4, 6, 10,
and 14) collected from the orbital plexus were treated with
receptor-destroying enzyme from Vibrio cholerae (Denka-
Seiken, Tokyo, Japan) as previously described (Katz et al.,
1997) before testing for the presence of HI antibody by
standard methods (Kendal et al., 1982). Individual mice
were considered to have responded to vaccination if serum
HI titers were 40. Titers of neutralizing antibody were
determined as previously described (Harmon et al., 1988).
Neutralization titers are expressed as the reciprocal of the
highest dilution of serum that gave 50% neutralization of
100 TCID50 of virus. Standard indirect ELISAs were per-
formed to assess anti-HA specific IgG levels in postvacci-
nation sera using 1 g/ml of purified recombinant HK/156
HA protein (Protein Sciences, Meriden, CT) to coat plates.
Endpoint titers are expressed as the reciprocal of the end-
point dilution of sample with an OD490 reading three times
the mean OD490 of wells that lacked primary antibody.
Influenza virus challenge
Fourteen weeks after the initial inoculation, mice were
lightly anesthetized with CO2 and challenged with 10
MLD50 of influenza virus HK/156 (H5N1) by intranasal
delivery of 50 l of allantoic fluid diluted in PBS. This
method leads to infection of both the upper and lower
respiratory tract and is lethal to 100% of nonimmunized
mice. Mice were monitored daily for both weight loss and
survival. Data are presented as the average percentage of the
prechallenge weight.
Statistics
Statistical analyses were performed using the Student’s
t-test to compare each modified HA to the HK156wt con-
struct. Statistical significance was considered when the P
value was 0.05.
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